Rising Gestational Diabetes Rates; Updated Hormone Therapy Statement; Insulin Recall

Rising Gestational Diabetes Rates; Updated Hormone Therapy Statement; Insulin Recall

July 21, 2022 0 By Jennifer Walker

The U.S. is seeing a rise in gestational diabetes rates, with a 30% jump from 2016 to 2020, the CDC reported.

Among 1,050 U.S. adults ages 45 and older, receiving federal rental assistance through project-based housing was tied with better HbA1c levels. (JAMA Network Open)

The highly anticipated $35 cap per month for insulin costs was dropped from the latest revised bill as part of the Democrats’ economic package. (The Hill)

In a Chinese study, people who were underweight (BMI below 18.5) tended to just eat less and have higher resting metabolic rates compared with people with a normal BMI (21.5 to 25), but weren’t any more physically active. (Cell Metabolism)

The North American Menopause Society released an updated hormone therapy position statement, saying the practice “remains the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture.” (Menopause)

Mylan Pharmaceuticals voluntarily recalled one batch of injectable insulin glargine pens due to possible missing labels, the FDA announced.

A Michigan-based endocrinologist, who owned and ran the solo practice Northern Michigan Endocrine, pleaded guilty to evading more than $250,000 in taxes, the Department of Justice announced.

A federal court in Florida dismissed a False Claims Act lawsuit that stemmed from a whistleblower alleging that Trividia Health was billing federal healthcare programs for defective blood glucose test strips. (Bloomberg Law)

  • author['full_name']

    Kristen Monaco is a staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.